JDRF Australia and Insulet Corporation Australia announce new partnership
JDRF Australia today announced a new partnership with Insulet Corporation Australia, an innovative medical device company, in a joint move to improve outcomes for the type one diabetes (T1D) community.
Insulet is part of a global network dedicated to making the lives of people with diabetes and other conditions easier through technology like its Omnipod DASH Insulin management system, which offer new alternatives for administering insulin.
Its partnership with JDRF will focus on supporting Australians managing T1D through raising awareness within the community about diabetes related products and technologies, and assisting in the development of community engagement programs, activities and projects.
It will also support JDRF’s aim to increase access to essential management technologies that have the ability to transform and streamline diabetes care.
Country manager of Insulet Corporation Australia, Joanna Sader, says the partnership is part of their commitment to the T1D community and an exciting move for the company.
“Our launch in Australia is a continuation of our global mission to improve the lives of people living with diabetes, and we’re thrilled to be partnering with JDRF Australia to support the fantastic work they are doing with the community.
“As we continue to drive innovation for T1D, we are focused on simplifying life for those Australians living with type 1 diabetes. We look forward to working together towards our mutual goal of greater access to technology that can transform diabetes care management.”
JDRF Australia CEO, Mike Wilson OAM, has welcomed the partnership, thanking Insulet for their commitment to JDRF and advancements for T1D.
“T1D is a challenging condition to manage. While we continue fund research to deliver a world without T1D, JDRF also welcomes the opportunity to partner with likeminded organisations who are innovative and passionate about supporting the community and lowering the burden of the day-to-day management of T1D.
Our industry partners are a vital part of the lived experience of the 127,000 Australians with T1D, as they are developing lifesaving and lifechanging technologies that have real impact. We look forward to working with Insulet on our shared goals.”
The partnership will initially focus on Insulet supporting JDRF’s work in advocacy as well as providing the community with regular updates on diabetes technologies and innovations.
To learn more about JDRF’s advocacy for the T1D community, click here.
For more information on the Omnipod, click here.
World-first Australian clinical trial shows promise for suppressing progression of type 1 diabetes in those newly diagnosed
A JDRF-funded, world-first clinical trial has shown that a commonly prescribed rheumatoid arthritis drug (baricitinib) can preserve the body’s own insulin production and suppress the progression of type 1 diabetes (T1D) in those newly diagnosed with the condition. This comes after three decades of research out of the St Vincent’s Institute (SVI) in Melbourne, led […]
New research funding may allow those with type 1 diabetes to make insulin again
JDRF has just funded a new Australian islet transplantation research project with the potential to revert type 1 diabetes. The benefits of islet transplantation Pancreatic islet transplantation is a life-saving and life-changing treatment currently available for people with type 1 diabetes (T1D) who are unaware of their dangerously low blood glucose levels (known as ‘severe […]
Regenerating damaged beta cells in type 1 diabetes ꟷ new funding announced.
JDRF has funded a new Australian research project which may allow those with type 1 diabetes (T1D) to regenerate lost pancreatic cells During T1D development, the immune system mistakenly attacks the insulin-producing beta cells in the pancreas. This leads to the loss and destruction of beta cells, meaning that people with T1D are no longer […]
Changes to the Federal Government’s Insulin Pump Program
The Australian Government’s Insulin Pump Program (IPP), administered by JDRF Australia, provides insulin pumps to young Australians up to the age of 21, living with type 1 diabetes (T1D), who meet certain financial and clinical eligibility requirements. The program supplies fully subsidised insulin pumps to people who would otherwise be unable to access insulin pump […]